alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 1313.33 Contents of an international transaction declaration. ( a ) An international transaction involving a chemical listed in § 1310.02 of this chapter which meets the threshold criteria established in § 1310.04 of this chapter may be arranged by a broker or trader if the chemical is needed for medical, commercial, scientific, or other legitimate uses.
( b ) Any broker or trader who desires to arrange an international transaction, defined in 21 U.S.C. 802(42), involving a listed chemical which meets the threshold criteria set forth in § 1310.04 of this chapter must notify the Administration through the procedures outlined in § 1313.32(b).
( c ) The DEA Form 486 must include: ( 1 ) The name/business name, address/business address, and contact information (*e.g.,* telephone number(s), email address(es), etc.) of the chemical exporter; the name/business name, address/business address, and contact information (*e.g.,* telephone number(s), email address(es), etc.) of the chemical importer;
( 2 ) The name and description of each listed chemical as it appears on the label or container, the name of each listed chemical as it is designated in § 1310.02 of this chapter, the size or weight of container, the number of containers, the net weight of each listed chemical given in kilograms or parts thereof, and the gross weight of the shipment given in kilograms or parts thereof;
( 3 ) The anticipated date of release at the foreign port of export, the anticipated foreign port and country of export, and the foreign port and country of entry; and
( 4 ) The name/business name, address/business address, and contact information (*e.g.,* telephone number(s), email address(es), etc.) of the consignee in the country where the chemical shipment is destined; the name(s) and address(es) of any intermediate consignee(s).
[60 FR 32465, June 22, 1995, as amended at 77 FR 4238, Jan. 27, 2012; 81 FR 97040, Dec. 30, 2016]
§ 520.390c Chloramphenicol palmitate oral suspension. ( a ) *Specifications.* Each milliliter contains chloramphenicol palmitate equivalent to 30 milligrams of chloramphenicol.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use. Dogs* — ( 1 ) *Amount.* 25 milligrams per pound of body weight every 6 hours. If no response is obtained in 3 to 5 days, discontinue use and reevaluate diagnosis.
( 2 ) *Indications for use.* Treatment of bacterial pulmonary infections, infections of the urinary tract, enteritis, and infections associated with canine distemper that are caused by organisms susceptible to chloramphenicol.
( 3 ) *Limitations.* Not for use in animals that are raised for food production. Must not be used in meat-, egg-, or milk-producing animals. The length of time that residues persist in milk or tissues has not been determined. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[57 FR 37323, Aug. 18, 1992; 57 FR 42623, Sept. 15, 1992, as amended at 79 FR 28819, May 20, 2014]
Exhibit 10.19(b)

FIRST AMENDMENT
TO THE 
PROGRAMMER'S PARADISE, INC.
2006 STOCK-BASED COMPENSATION PLAN

In accordance with the power reserved to it in Section 20(a) of the Programmer's Paradise, Inc. 2006 Stock-Based Compensation Plan (the "Plan"), the Board of Directors of Programmer's Paradise, Inc. (the "Company") hereby amends the Plan, effective July 5, 2006 as follows:

1. Section 2(h) is amended to correct a typographical error to read as
follows:

> " 'Common Stock' means the common stock of  Programmer's Paradise, Inc., par value $0.01 per share".

2.  Section 8(d)(ii) is amended in its entirety to read as follows:

> "(ii) Unless otherwise determined by the Committee, dividends will be authorized by Programmer's Paradise, Inc. to be paid to the Participant during the period the restriction is enforced, subject to the same restrictions as the underlying shares upon which the dividend is declared."

*  *  *  *  *







To record the adoption of this First Amendment to the Plan, the Company has caused its authorized officers to affix its corporate name and seal this
24th day of August, 2006.

|[CORPORATE SEAL] | PROGRAMMER'S PARADISE, INC.
|---------------- | ---------------------------
|                 |                            
|Attest:          | /s/ Kevin Scull            
|                 |
§ 352.10 Sunscreen active ingredients. The active ingredient of the product consists of any of the following, within the concentration specified for each ingredient, and the finished product provides a minimum SPF value of not less than 2 as measured by the testing procedures established in subpart D of this part: ( a ) Aminobenzoic acid (PABA) up to 15 percent.
( b ) Avobenzone up to 3 percent.
( c ) Cinoxate up to 3 percent.
( d ) [Reserved]
( e ) Dioxybenzone up to 3 percent.
( f ) Homosalate up to 15 percent.
( g ) [Reserved]
( h ) Menthyl anthranilate up to 5 percent.
( i ) Octocrylene up to 10 percent.
( j ) Octyl methoxycinnamate up to 7.5 percent.
( k ) Octyl salicylate up to 5 percent.
( l ) Oxybenzone up to 6 percent.
( m ) Padimate O up to 8 percent.
( n ) Phenylbenzimidazole sulfonic acid up to 4 percent.
( o ) Sulisobenzone up to 10 percent.
( p ) Titanium dioxide up to 25 percent.
( q ) Trolamine salicylate up to 12 percent.
( r ) Zinc oxide up to 25 percent.
[64 FR 27687, May 21, 1999] Effective Date Note
Effective Date Note: At 67 FR 41823, June 20, 2002, § 352.10 was amended by revising paragraphs (f) through (n), effective Sept. 1, 2002. This amendment could not be incorporated because at 66 FR 67485, Dec. 31, 2001, the effective date was stayed until further notice. For the convenience of the user, the revised text is set forth as follows: § 352.10 Sunscreen active ingredients. (f) Ensulizole up to 4 percent. (g) Homosalate up to 15 percent. (h) [Reserved] (i) Meradimate up to 5 percent. (j) Octinoxate up to 7.5 percent. (k) Octisalate up to 5 percent. (l) Octocrylene up to 10 percent. (m) Oxybenzone up to 6 percent. (n) Padimate O up to 8 percent.
SERVED: AUGUST 20, 2010 

U.S. DEPARTMENT OF TRANSPORTATION 

OFFICE OF HEARINGS 

WASHINGTON, DC 

IN THE MATTER OF 

HARRISON YACHT SALES, INC. 

FAA DOCKET NO. CP10EA0006 

(Civil Penalty Action) 

FDMS NO. FAA-2010-0626 

NOTICE OF ASSIGNMENT OF PROCEEDING 

This proceeding (heretofore designated as Case No. 2009EA700446) has been assigned 

to the undersigned. All future pleadings and other communications regarding this proceeding 

shall be served on the Judge, the FAA Hearing Docket, and the other persons on the attached 

Service List. 

lie A. Yoder 

Chief Administrative La 

Attachment - Service List 
FAA Docket No. CP10EA0006 

(Civil Penalty Action) 

SERVICE LIST 

ORIGINAL & ONE COPY 

Federal Aviation Administration 

800 Independence Avenue, S.W. 

Washington, DC 20591 

Attention: Hearing Docket Clerk, AGC-430 

Wilbur Wright Building - Suite 2W1000* 

ONE COPY 

David Harrison, President 

Harrison Yacht Sales, Inc., Respondent 

106 Wells Cove Road 

P.O. Box 98 

Grasonville,MD 21638 

TEL: 401-827-7800 

FAX: 410-827-4830 

Mary MadeUne McCarthy, Complainant's Counsel 

Attorney, Office of the Regional Counsel, EAL-7 

Federal Aviation Administration 

1 Aviation Plaza 

Jamaica, NY 11434 

TEL: 718-553-3267 

FAX: 718-995-5699 

The Honorable Ronnie A. Yoder, Chief Administrative Law Judge 

U.S. Department of Transportation 

Office of Hearings, M-20, Room El 2-320 

1200 New Jersey Avenue, S.E. 

Washington, DC 20590 

TEL: 202-366-2142 

FAX: 202-366-7536 

' Service was by U.S. Mail. For service in person or by expedited courier, use the following address: 

Federal Aviation Administration, 600 Independence Avenue, S.W., Wilbur Wright Building - Suite 2W1000, 

Washington, DC 20591, Attention: Hearing Docket Clerk, AGC-430.
Editorial Note on Part 201
Editorial Note: Nomenclature changes to part 201 appear at 69 FR 13717, Mar. 24, 2004.

§ 201.21 Declaration of presence of phenylalanine as a component of aspartame in over-the-counter and prescription drugs for human use. ( a ) Aspartame is the methylester of a dipeptide composed of two amino acids, phenylalanine and aspartic acid. When these two amino acids are so combined to form aspartame (1-methyl *N*-L-α-aspartyl-L-phenylalanine), they produce an intensely sweet-tasting substance, approximately 180 times as sweet as sucrose. The Food and Drug Administration has determined that aspartame when used at a level no higher than reasonably required to perform its intended technical function is safe for use as an inactive ingredient in human drug products, provided persons with phenylketonuria, who must restrict carefully their phenylalanine intake, are alerted to the presence of phenylalanine in the drug product and the amount of the ingredient in each dosage unit.
( b ) The label and labeling of all over-the-counter human drug products containing aspartame as an inactive ingredient shall bear a statement to the following effect: Phenylketonurics: Contains Phenylalanine (_)mg Per (Dosage Unit).
( c ) The package labeling and other labeling providing professional use information concerning prescription drugs for human use containing aspartame as an inactive ingredient shall bear a statement to the following effect under the “Precautions” section of the labeling, as required in § 201.57(f)(2): Phenylketonurics: Contains Phenylalanine (_)mg Per (Dosage Unit).
( d ) Holders of approved new drug applications who reformulate their drug products under the provisions of this section shall submit supplements under § 314.70 of this chapter to provide for the new composition and the labeling changes.
(Approved by the Office of Management and Budget under control number 0910-0242) [52 FR 2111, Jan. 20, 1987; 52 FR 12152, Apr. 15, 1987; 53 FR 4135, Feb. 12, 1988]
### TEXA S C OU R T OF A PPEAL S, THIR D DIST R ICT , AT AU STIN NO. 03-0 7 -00 138 -CV Ca r l D ixo n d/b/ a D ixo n Co nt r ac ti ng , A ppe lla nt

v . Doug Gr oves and Pat ty G roves , Appellees F ROM COUNTY COURT AT LAW NO. 4 OF WILLI AMSO N COUNTY NO. 06- 0046 -CC4 , HO NORAB LE JO HN M CMASTER , JUDGE PRESIDI NG

M E M O R

A N D UM O P I N I O N Th e pa rt ie s h ave fi le d a jo int

mot ion to v a c ate the tr ia l c ourt ’s jud g me nt a nd dis mis s the ca se with prejudice to ref i l i n g, as ag ree d to in their Rule 11 settlement ag ree ment. This court has the a uthority to rende r judg ment eff

ectuating the p ar t i es ’ agr eeme nt. SeeTe x. R. A pp . P. 42.1(a) (2)( A). Acc ording ly , we vacate the t rial court’s judgme nt and dis miss the case with prejudice to refile. SeeTex. R. App. P . 43.2(e) (may vacate and dismiss case) .

W. Kenneth L aw, Chief Justice Be fore Chief J ustice L aw, Justi ces Puryear and He nson Vac ated a nd Cause Dismissed on J oint Moti on Filed: Apr il 18, 2007
§ 500.51 Labeling of animal drugs; misbranding. ( a ) Among the representations on the label or labeling of an animal drug which will render the drug misbranded are any broad statements suggesting or implying that the drug is not safe and effective for use when used in accordance with labeling direction, or suggesting or implying that the labeling does not contain adequate warnings or adequate directions for use. Such statements include, but are not limited to: ( 1 ) Any statement that disclaims liability when the drug is used in accordance with directions for use contained on the label or labeling.
( 2 ) Any statement that disclaims liability when the drug is used under “abnormal” or “unforeseeable” conditions.
( 3 ) Any statement limiting the warranty for the products to a warranty that the drug in the package contains the ingredients listed on the label.
( b ) This regulation is not intended to prohibit any liability disclaimer that purports to limit the amount of damages or that sets forth the legal theory under which damages are to be recovered.
( c ) Any person wishing to obtain an evaluation of an animal drug liability disclaimer under this regulation may submit it to Division of Compliance, (HFV-230), Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855. A supplemental NADA providing appropriately revised labeling shall be submitted for any approved new animal drug the labeling of which is not in compliance with this regulation.
[41 FR 8473, Feb. 27, 1976, as amended at 54 FR 18279, Apr. 28, 1989; 57 FR 6475, Feb. 25, 1992]
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
This schedule contains summary information extracted from the financial
statements in the Company's Annual Report on Form 10-K for the year ended
December 31, 1996.
</LEGEND>
<MULTIPLIER> 1
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-END>                               DEC-31-1996
<CASH>                                       8,133,468
<SECURITIES>                                 1,949,039
<RECEIVABLES>                               10,779,477
<ALLOWANCES>                                   221,000
<INVENTORY>                                  1,851,713
<CURRENT-ASSETS>                            22,893,284
<PP&E>                                         481,421
<DEPRECIATION>                                  75,046
<TOTAL-ASSETS>                              30,243,378
<CURRENT-LIABILITIES>                        3,722,513
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         3,452
<OTHER-SE>                                  26,517,413
<TOTAL-LIABILITY-AND-EQUITY>                30,243,378
<SALES>                                     24,648,928
<TOTAL-REVENUES>                            25,309,977
<CGS>                                       16,248,469
<TOTAL-COSTS>                               16,248,469
<OTHER-EXPENSES>                             6,075,878
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                              3,689,374
<INCOME-TAX>                                 1,498,000
<INCOME-CONTINUING>                          2,191,374
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 2,191,374
<EPS-PRIMARY>                                     0.31
<EPS-DILUTED>                                     0.31
        

</TABLE>
EXHIBIT 31  SECTION 302 CERTIFICATIONS

I, Theodore L. Arena, and I, Thomas J. Mulroney, each separately certify that:

1. I have reviewed this quarterly report on Form 10-Q of Provena Foods Inc. (the Company);

2. Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by
this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;

4. The
Companys other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and l5d-15(e)) for the Company and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the Company, including any subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Evaluated the effectiveness of the Companys disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

c) Disclosed in this report any change in the Companys internal control over financial reporting that occurred during the Companys most recent fiscal quarter that has materially affected, or is reasonably likely to materially
affect, the Companys internal control over financial reporting; and

5. The Companys other certifying officer and I have disclosed, based on
our most recent evaluation of internal control over financial reporting, to the Companys auditors and the audit committee of the Companys board of directors:

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Companys ability to record,
process, summarize and report financial information; and

b) Any fraud. whether or not material, that involves management or other
employees who have a significant role in the Companys internal control over financial reporting.

Date: August 9, 2006



|                                           
|-------------------------------------------
|/s/ THEODORE L.
ARENA                      
|Theodore L. Arena, Chief Executive Officer 
|/s/ THOMAS J.
MULRONEY                     
|Thomas J. Mulroney, Chief Financial Officer
38767.

#### HART v. BROOKS.

Carlisle, Judge.

1. While a brief of the evidence is not required for a consideration of grounds of motion for a new trial, the merits of which can be ascertained without reference to the evidence (Ga. L. 1947, p. 298; *Code Ann.*§ 70-301.1), it is always essential in passing upon what are commonly referred to as the “general grounds” of a motion that the court consider the evidence. Accordingly, the first grant of a new trial by the trial judge on the ground that “the verdict was contrary to law and the principles of justice and equity” was illegal where the motion containing such ground was not accompanied by a brief of evidence, submitted for approval prior to the consideration by the court of such ground. *Murry v. Snyder,*91 Ga. App. 456 (2b) (85 S. E. 2d 823).

2. Where after the call of the case and before striking the jury counsel for the plaintiff requested the court to qualify the panel as to their relationship by blood or marriage to the parties in the case, and where none of the jurors so questioned disqualified themselves; and, where immediately prior to *471striking the jury one of the attorneys for the defendant informed the court that the defendant thought that a named person on the panel was related to him within the prohibited degree; and, where the said prospective juror was then individually asked by the court if he was related to the defendant and he denied such relationship, and where thereafter the panel was put upon the parties and the plaintiff took no further action to ascertain the truth as to such relationship but merely struck such panel member peremptorily, she will be held to have waived it, and it was too late, after the introduction of evidence and a verdict had been rendered by the jury in favor of the defendant, for the plaintiff to raise any issue by motion for a new trial respecting such relationship. After being put on notice by the announcement of the defendant of the probable relationship of the panel member to' the defendant, the plaintiff failed to exercise due diligence in ascertaining the true relationship when she failed to examine the juror or at least to put the defendant who had called attention to the relationship on the stand in order to take his testimony under oath as to' his knowledge of the true facts respecting such relationship. *Jennings v. Autry,*94 Ga. App. 344 (94 S. E. 2d 629). Under the provisions of the act approved February 19, 1951 (Ga. L. 1951, pp. 214, 216), the plaintiff had the right not only to examine the juror as to his relationship but to put in such relevant evidence as she saw fit in order to present to the court the truth of the matter. It follows that the trial judge erred in granting a new trial on the special ground of the motion complaining of such relationship.

Decided April 5, 1961.

*Wyatt & Morgan, James R. Lewis, H. T. Quillian, Jr.,*for plaintiffs in error.

*E. W. Fleming, Loeb C. Ketzky,*contra.

*Judgment reversed.*

*Townsend, P.J., Frankum and Jordan, JJ., concur.*
§ 522.147 Atipamezole. ( a ) *Specifications.* Each milliliter of solution contains 5.0 milligrams atipamezole hydrochloride.
( b ) *Sponsors.* See Nos. 015914, 052483, 068504, and 069043 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* Administer 3,750 mcg/m2 intramuscularly for the reversal of intravenous dexmedetomidine hydrochloride or medetomidine hydrochloride and 5,000 mcg/m2 intramuscularly for the reversal of intramuscular dexmedetomidine hydrochloride or medetomidine hydrochloride.
( 2 ) *Indications for use.* For the reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride and medetomidine hydrochloride.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[61 FR 48830, Sept. 17, 1996, as amended at 64 FR 71640, Dec. 22, 1999; 72 FR 264, Jan. 4, 2007; 84 FR 8973, Mar. 13, 2019; 88 FR 84700, Dec. 6, 2023; 89 FR 42357, May 15, 2024]
§ 520.1330 Meclofenamic acid granules. ( a ) *Specifications.* Each gram of granules contains 5 milligrams (5 percent) meclofenamic acid.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in horses* — ( 1 ) *Amount.* Administer 1 milligram per pound of body weight (1 gram per 1000 pounds) once daily for 5 to 7 days by addition to the daily grain ration.
( 2 ) *Indications for use.* For the treatment of acute or chronic inflammatory diseases involving the musculoskeletal system.
( 3 ) *Limitations.* Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[78 FR 28824, May 20, 2014]
[Federal Register Volume 75, Number 36 (Wednesday, February 24, 2010)]
[Notices]
[Page 8416]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-3792]


-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION


Sunshine Act Meeting

    Notice is hereby given, pursuant to the provisions of the 
Government in the Sunshine Act, Public Law 94-409, that the Securities 
and Exchange Commission will hold an Open Meeting on February 24, 2010 
at 10 a.m., in the Auditorium, Room L-002.
    Commissioner Casey, as duty officer, determined that no earlier 
notice thereof was possible.
    The subject matter of the Open Meeting will be:
    Item 1: The Commission will consider whether to adopt amendments to 
Rules 201 and 200(g) of Regulation SHO relating to short sale 
restrictions.
    Item 2: The Commission will consider whether to publish a statement 
regarding its continued support for a single-set of high-quality 
globally accepted accounting standards and its ongoing consideration of 
incorporating International Financial Reporting Standards into the 
financial reporting system for U.S. issuers.
    At times, changes in Commission priorities require alterations in 
the scheduling of meeting items.
    For further information and to ascertain what, if any, matters have 
been added, deleted or postponed, please contact:
    The Office of the Secretary at (202) 551-5400.

    Dated: February 19, 2010.
Elizabeth M. Murphy,
Secretary.
[FR Doc. 2010-3792 Filed 2-22-10; 11:15 am]
BILLING CODE 8011-01-P